<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02462239</url>
  </required_header>
  <id_info>
    <org_study_id>OCOG-2013-PETMUSE</org_study_id>
    <nct_id>NCT02462239</nct_id>
  </id_info>
  <brief_title>Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging</brief_title>
  <acronym>PET MUSE</acronym>
  <official_title>Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ontario Clinical Oncology Group (OCOG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Care Ontario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ontario Clinical Oncology Group (OCOG)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bladder cancer is the fifth most common cancer in Canada and there has been relatively little
      progress in altering its clinical course over the last three decades. One of the major
      problems identified in the management of this disease, is under staging of muscle invasive
      disease which can lead to suboptimal treatment and outcomes. PET-CT has the potential to more
      accurately stage MIBC than standard CT by detecting pelvic adenopathy and/or distant sites of
      disease that may not be found on standard imaging. In the former situation, more aggressive
      therapy with extended lymph node dissection and/or neoadjuvant chemotherapy prior to
      cystectomy can be offered. While in the latter situation patients can be spared the morbidity
      of a cystectomy performed in a setting of metastatic disease. This study will address whether
      PET-CT adds a clinically meaningful difference in care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter randomized controlled trial will be performed. Patients usually present with
      symptoms (e.g., painless hematuria). The urologist will perform cystoscopy and if urothelial
      cancer of the bladder is suspected, the patient is taken to the operating room for an
      examination under anesthesia (EUA) and a TURBT. If this shows muscle invasion then
      conventional staging with CT chest, abdomen, and pelvis is performed. The patient who has TNM
      Stage T2a-T4a N0-3 M0 is eligible to be enrolled in the trial. Eligible consenting patients
      will be randomized 2:1 to PET-CT or none (Control). The actual treatment received by the
      patient will be documented. The primary outcome measure is treatment received.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment received</measure>
    <time_frame>5 years</time_frame>
    <description>For patients with planned cystectomy, treatment received includes: avoidance of planned cystectomy and node dissection, an extended (vs standard) node dissection (or standard dissection when extended is the surgeon's usual practice), use of neoadjuvant chemotherapy (vs no neoadjuvant chemotherapy). For patients with planned bladder conservation, treatment received includes: avoidance of bladder and nodal radiation (vs bladder only or no radiation) and use of neoadjuvant chemotherapy (or not).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Disease-free survival defined as objectively defined (RECIST criteria, version 1.1.) local or distant recurrence or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival defined by all-cause mortality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life analysis</measure>
    <time_frame>5 years</time_frame>
    <description>Overall QOL assessed using the EORTC QLQ-C30 version 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economic analysis</measure>
    <time_frame>5 years</time_frame>
    <description>Health economic analysis assessed using EQ-5D health utility questionnaire and total healthcare costs.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in planned management</measure>
    <time_frame>5 years</time_frame>
    <description>Assess change in planned management with actual treatment delivered in both pre-operative PET-CT versus no PET-CT (control) patients.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical and pathology response to chemotherapy using interim response of FDG PET-CT after 2 cycles of chemotherapy</measure>
    <time_frame>5 years</time_frame>
    <description>Explore if interim response on FDG PET-CT after 2 cycles of chemotherapy is associated with clinical and pathology response to chemotherapy and if early interim metabolic response correlates with other outcome measures including DFS and OS.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">291</enrollment>
  <condition>Muscle-invasive Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Whole-body FDG PET-CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Whole-body FDG PET-CT (Experimental arm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No PET-CT</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No PET-CT (Control arm)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Whole-body FDG PET-CT</intervention_name>
    <arm_group_label>Whole-body FDG PET-CT</arm_group_label>
    <other_name>PET-CT imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women with newly diagnosed muscle-invasive high grade urothelial carcinoma of
             the bladder (TNM stage T2a-T4a, N0-3, M0), who are eligible for either radical
             cystectomy or radiotherapy-based bladder conservation.

          -  Being considered for treatment of curative intent.

        Exclusion Criteria:

          -  Age &lt; 18 years.

          -  ECOG performance status &gt;2.

          -  Predominant histology (&gt;50% of specimen) involves non-urothelial cell carcinoma.

          -  Prior partial cystectomy.

          -  Prior pelvis surgery that obviates a completed extended lymphadenectomy (e.g.,
             aorto-femoral/iliac bypass) or for whom the surgeon feels that their ability to
             perform a standard or extended pelvic node dissection would be compromised.

          -  Contraindications to FDG PET-CT.

          -  Inability to lie supine for imaging with PET-CT.

          -  Inadequate hepatic function:

             (i) Bilirubin &gt;1.5 X ULN and (ii) SGOT and Alkaline phosphatase &gt;3 X ULN

          -  History of another invasive malignancy within the previous 5 years with the exception
             of non-melanoma skin cancer.

          -  Known pregnancy or lactating female.

          -  Inability to complete the study or required follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Srikala Sridhar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicholas Power, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LHSC-Victoria Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Som Mukherjee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Juravinski Cancer Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ur Metser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Levine, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ontario Clinical Oncology Group (OCOG)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc L Filion, MSc, CCRP</last_name>
    <phone>905-527-2299</phone>
    <phone_ext>42611</phone_ext>
    <email>filion@mcmcaster.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Som Mukherjee, MD</last_name>
      <phone>905-387-9495</phone>
      <email>mukherjee@hhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Som Mukherjee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Power, MD</last_name>
      <email>Nicholas.Power@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Eric Winquist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Regional Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodney Breau, MD</last_name>
      <phone>613-737-8899</phone>
      <email>rbreau@ottawahospital.on.ca</email>
    </contact>
    <investigator>
      <last_name>Rodney Breau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thunder Bay Regional Health Sciences Centre</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dolores Sicheri, MD</last_name>
      <email>sicherid@tbh.net</email>
    </contact>
    <investigator>
      <last_name>Dolores Sicheri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanna Cheng, MD</last_name>
      <phone>416-480-4928</phone>
      <email>susanna.cheng@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Susanna Cheng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Srikala Sridhar, MD</last_name>
      <email>Srikala.Sridhar@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Srikala Sridhar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2015</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Muscle-invasive bladder cancer</keyword>
  <keyword>Bladder cancer</keyword>
  <keyword>PET imaging</keyword>
  <keyword>FDG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

